Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus
- PMID: 16968900
- DOI: 10.1182/blood-2006-03-009670
Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus
Abstract
Four of 9 PAX transcription factor genes have been associated with chromosomal translocations in human tumors, although their oncogenic potential has not yet been demonstrated in transgenic mouse models. The B-lymphoidPAX5 gene participates in the generation of the t(9;14)(p13;q32) translocation in germinal center B cells, which leads to deregulated PAX5 expression under the control of the immunoglobulin heavy-chain (IgH) locus in a subset of B-cell non-Hodgkin lymphomas. Here we reconstructed a human t(9;14) translocation in a knock-in mouse by inserting a PAX5 minigene into the IgH locus. The IgH(P5ki) allele, which corresponds to a germline rather than somatic mutation, is activated in multipotent hematopoietic progenitors and is subsequently expressed in dendritic cells (DCs) and in natural killer (NK), T, and B cells. Ectopic Pax5 expression interferes with normal T-cell development and causes immature T-lymphoblastic lymphomas in IgH(P5ki/+) and IgH(P5ki/P5ki) mice. Aggressive T-cell lymphomas develop even faster in Ik(Pax5/+) mice expressing Pax5 from the Ikaros locus. Pax5 expression in thymocytes activates B-cell-specific genes and represses T-lymphoid genes, suggesting that Pax5 contributes to lymphomagenesis by deregulating the T-cell gene-expression program. These data identify Pax5 as a potent oncogene and demonstrate that the T-lymphoid lineage is particularly sensitive to the oncogenic action of Pax5.
Similar articles
-
Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma.Blood. 1998 Nov 15;92(10):3865-78. Blood. 1998. PMID: 9808580
-
Diffuse large B-cell lymphoma carrying t(9;14)(p13;q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry.Hematol Oncol. 2020 Apr;38(2):171-180. doi: 10.1002/hon.2716. Epub 2020 Feb 16. Hematol Oncol. 2020. PMID: 31955451
-
The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene.Blood. 1996 Dec 1;88(11):4110-7. Blood. 1996. PMID: 8943844
-
t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma.Int J Hematol. 1999 Feb;69(2):65-9. Int J Hematol. 1999. PMID: 10071452 Review.
-
The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.Leuk Lymphoma. 2000 Feb;36(5-6):435-45. doi: 10.3109/10428190009148390. Leuk Lymphoma. 2000. PMID: 10784387 Review.
Cited by
-
PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10357-10362. doi: 10.1073/pnas.1721678115. Epub 2018 Sep 26. Proc Natl Acad Sci U S A. 2018. PMID: 30257940 Free PMC article.
-
Unusual presentation of primary T-cell lymphoblastic lymphoma: description of two cases.Diagn Pathol. 2014 Jun 20;9:124. doi: 10.1186/1746-1596-9-124. Diagn Pathol. 2014. PMID: 24950962 Free PMC article.
-
B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.J Clin Invest. 2007 Sep;117(9):2602-10. doi: 10.1172/JCI30842. J Clin Invest. 2007. PMID: 17717600 Free PMC article.
-
Structural basis of DUX4/IGH-driven transactivation.Leukemia. 2018 Jun;32(6):1466-1476. doi: 10.1038/s41375-018-0093-1. Epub 2018 Mar 15. Leukemia. 2018. PMID: 29572508 Free PMC article.
-
PAX5 alterations in B-cell acute lymphoblastic leukemia.Front Oncol. 2022 Oct 25;12:1023606. doi: 10.3389/fonc.2022.1023606. eCollection 2022. Front Oncol. 2022. PMID: 36387144 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases